AZ, Amgen’s SOURCE trial misses primary endpoint
admin 22nd December 2020 Uncategorised 0New medicine tezepelumab is being studied in severe asthma More: AZ, Amgen’s SOURCE trial misses primary endpoint Source: News
read more
New medicine tezepelumab is being studied in severe asthma More: AZ, Amgen’s SOURCE trial misses primary endpoint Source: News
read moreFollows positive opinion issued by EMA’s CHMP More: Pfizer, BioNTech win EU authorisation for COVID-19 vaccine Comirnaty Source: News
read moreMyovant scores FDA nod for Orgovyx, a first-in-class pill for advanced prostate cancer esagonowsky Mon, 12/21/2020 – 11:31 More: Myovant scores FDA nod for Orgovyx, a first-in-class pill for advanced prostate cancer Source: fierce
read moreWuXi lays out €150M to take over Bayer plant in Germany, boosting pandemic supply network fkansteiner Mon, 12/21/2020 – 11:29 More: WuXi lays out €150M to take over Bayer plant in Germany, boosting pandemic supply network Source: fierce
read morePick the Commish: Fierce Pharma voters select Amy Abernethy for next FDA chief bbulik Mon, 12/21/2020 – 10:40 More: Pick the Commish: Fierce Pharma voters select Amy Abernethy for next FDA chief Source: fierce
read moreCodagenix, Serum Institute take nasal COVID-19 vaccine into clinic ntaylor Mon, 12/21/2020 – 09:48 More: Codagenix, Serum Institute take nasal COVID-19 vaccine into clinic Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals